Stock ACLX ARCELLX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Arcellx, Inc.

Equities

ACLX

US03940C1009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
50.02 USD -2.13% Intraday chart for Arcellx, Inc. -8.12% -9.87%
Apr. 18 Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing MT
Apr. 03 Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $633,582, According to a Recent SEC Filing
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Arcellx, Inc. Enters an Assignment of Lease with A Third Party Sublessee
Arcellx Insider Sold Shares Worth $419,926, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $1,606,804, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $470,551, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $6,020,281, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $24,774,441, According to a Recent SEC Filing
Arcellx Phase 1 Expansion Study Data for Cancer Candidate Shows 100% Overall Response Rate
Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Sector Update: Health Care
Arcellx Expands Partnership With Gilead Unit Kite
Arcellx, Inc. and Kite Announces Expansion in Strategic Partnership
Arcellx Q3 Net Loss Narrows
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACLX Stock
  4. News Arcellx, Inc.
  5. Other languages